Generic Lexapro (escitalopram oxalate) took a hefty bite out of Forest Laboratories fourth-quarter sales which fell 9% to $997 million, compared to $1 billion for the same period last year (Forest's fiscal year ended March 31). Sales for the company's anti-depressant/anti-anxiety drug Lexapro tanked 40% to $356 million for the fiscal fourth quarter, compared to $595 million for the same period last year. Despite the changeover, the generic version provided $17 million worth of ballast, the result of distribution agreement with Mylan, which makes it. Products with an upward curve included blood-pressure drug Bystolic, which saws sales reach $97 million during the quarter, up 33% compared with the fourth quarter of fiscal year 2011. Sales for Alzheimer's drug Namenda rose 20%, to $391 million compared to the same period last year. The company said it also upped its SG&A expenses 17% for the quarter, to $411 million, compared to $352 million. Forest said the increase was part of its sales and marketing support for the following drugs: antibiotic Teflaro (ceftaroline fosamil), COPD treatment Daliresp (roflumilast) and major depressive disorder treatment Viibryd (vilazodone HCI).
This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.